Antidepressant hyperforin up-regulates VEGF in CNS tumour cells

Pharmacological Research

Volumn 63, Issue 1, 2011, Pages 37-43

  Tassone, Evelyne ^a   Maran, Claudio ^a   Masola, Valentina ^a   Bradaschia, Alice ^a   Garbisa, Spiridione ^a   Onisto, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

CNS tumours; Hyperforin; VEGF

Indexed keywords

GELATINASE A; GELATINASE B; HYPERFORIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE ACTIVITY; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; UPREGULATION;

ANTIDEPRESSIVE AGENTS; APOPTOSIS; BICYCLO COMPOUNDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 9; MEDULLOBLASTOMA; NEOVASCULARIZATION, PHYSIOLOGIC; PHLOROGLUCINOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TERPENES; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79151469747     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.09.005     Document Type: Article

References (43)

1. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
2. A.M. Byrne, D.J. Bouchier-Hayes, and J.H. Harmey Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med 9 2005 777 794
3. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
4. R.K. Jain, E. di Tomaso, D.G. Duda, J.S. Loeffler, A.G. Sorensen, and T.T. Batchelor Angiogenesis in brain tumours Nat Rev Neurosci 8 2007 610 622
5. H. Huang, J. Held-Feindt, R. Buhl, H.M. Mehdorn, and R. Mentlein Expression of VEGF and its receptors in different brain tumors Neurol Res 27 2005 371 377
6. M.C. Brahimi-Horn, and J. Pouyssegur HIF at a glance J Cell Sci 122 2009 1055 1057
7. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027
8. M.L. Slongo, B. Molena, A.M. Brunati, M. Frasson, M. Gardiman, and M. Carli Functional VEGF and VEGF receptors are expressed in human medulloblastomas Neuro Oncol 9 2007 384 392
9. R. Masood, J. Cai, T. Zheng, D.L. Smith, D.R. Hinton, and P.S. Gill Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors Blood 98 2001 1904 1913
10. R. Ran, H. Xu, A. Lu, M. Bernaudin, and F.R. Sharp Hypoxia preconditioning in the brain Dev Neurosci 27 2005 87 92
11. J.L. Warner-Schmidt, and R.S. Duman VEGF as a potential target for therapeutic intervention in depression Curr Opin Pharmacol 8 2008 14 19
12. J.L. Warner-Schmidt, and R.S. Duman VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants Proc Natl Acad Sci USA 104 2007 4647 4652
13. V. Butterweck, and M. St. Schmidt John's wort: role of active compounds for its mechanism of action and efficacy Wien Med Wochenschr 157 2007 356 361
14. T. Mennini, and M. Gobbi The antidepressant mechanism of hypericum perforatum Life Sci 75 2004 1021 1027
15. W.E. Muller, and St. Current John's wort research from mode of action to clinical efficacy Pharmacol Res 47 2003 101 109
16. M. Don, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, and M. Della Barbera Hyperforin inhibits cancer invasion and metastasis Cancer Res 64 2004 6225 6232
17. S. Garbisa, L. Sartor, S. Biggin, B. Salvato, R. Benelli, and A. Albini Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate Cancer 91 2001 822 832
18. Chatterjee SS, Erdelmeier C, Klessing K, Marmé D, Schächtele C. Stable hyperforin salts: method for producing them and their use in the treatment of Alzheimer's disease. PCT WO 99/41220; 1999.
19. R. Binetruy-Tournaire, C. Demangel, B. Malavaud, R. Vassy, S. Rouyre, and M. Kraemer Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis EMBO J 19 2000 1525 1533
20. V. Masola, C. Maran, E. Tassone, A. Zin, A. Rosolen, and M. Onisto Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion BMC Cancer 9 2009 304 313
21. M. Kubista, J.M. Andrade, M. Bengtsson, A. Forootan, J. Jonak, and K. Lind The real-time polymerase chain reaction Mol Aspects Med 27 2006 95 125
22. L. Nardinocchi, R. Puca, D. Guidolin, A.S. Belloni, G. Bossi, and C. Michiels Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth Biochim Biophys Acta 1793 2009 368 377
23. V. Di Stefano, M. Mattiussi, A. Sacchi, and G. D'Orazi HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations FEBS Lett 579 2005 5473 5480
24. A.B. Zimrin, B. Villeponteau, and T. Maciag Models of in vitro angiogenesis: endothelial cell differentiation on fibrin but not matrigel is transcriptionally dependent Biochem Biophys Res Commun 213 1995 630 638
25. D. Guidolin, A. Vacca, G.G. Nussdorfer, and D. Ribatti A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the matrigel assay in vitro Microvasc Res 67 2004 117 124
26. P.D. Brown, R.E. Bloxidge, E. Anderson, and A. Howell Expression of activated gelatinase in human invasive breast carcinoma Clin Exp Metastasis 11 1993 183 189
27. S. Garbisa, S. Biggin, N. Cavallarin, L. Sartor, R. Benelli, and A. Albini Tumor invasion: molecular shears blunted by green tea Nat Med 5 1999 1216
28. D. Grimm, J. Bauer, and J. Schoenberger Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases Curr Vasc Pharmacol 7 2009 347 357
29. B.J. Nieves, P.A. D'Amore, and B.A. Bryan The function of vascular endothelial growth factor Biofactors 35 2009 332 337
30. M. Shibuya Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor FEBS J 276 2009 4636 4643
31. K. Behnke, G.S. Jensen, H.J. Graubaum, and J. Gruenwald Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression Adv Ther 19 2002 43 52
32. A. Biber, H. Fischer, A. Romer, and S.S. Chatterjee Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers Pharmacopsychiatry 31 1998 36 43
33. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1999 9 22
34. C. Quiney, C. Billard, P. Mirshahi, J.D. Fourneron, and J.P. Kolb Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells Leukemia 20 2006 583 589
35. Y. Mizukami, Y. Kohgo, and D.C. Chung Hypoxia inducible factor-1 independent pathways in tumor angiogenesis Clin Cancer Res 13 2007 5670 5674
36. G. Pages, and J. Pouyssegur Transcriptional regulation of the vascular endothelial growth factor gene - a concert of activating factors Cardiovasc Res 65 2005 564 573
37. M. Hägg, and S. Wennström Activation of hypoxia-induced transcription in normoxia Exp Cell Res 306 2005 180 191
38. B. Kraus, H. Wolff, E.F. Elstner, and J. Heilmann Hyperforin is a modulator of inducible nitric oxide synthase and phagocytosis in microglia and macrophages Naunyn Schmiedebergs Arch Pharmacol 381 2010 541 553
39. D.S. Grant, K. Tashiro, B. Segui-Real, Y. Yamada, G.R. Martin, and H.K. Kleinman Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro Cell 58 1989 933 943
40. G. Lorusso, N. Vannini, I. Sogno, L. Generoso, S. Garbisa, and D.M. Noonan Mechanisms of hyperforin as an anti-angiogenic angioprevention agent Eur J Cancer 45 2009 1474 1484
41. A.G. Arroyo, L. Gens, P. Gonzalo, S. Matías-Román, A. Pollán, and B.G. Gálvez Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease Curr Pharm Des 13 2007 1787 1802
42. M. Garofalo, G. Di Leva, G. Romano, G. Nuovo, S.S. Suh, and A. Ngankeu miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation Cancer Cell 16 2009 498 509
43. G. Gabriely, T. Wurdinger, S. Kesari, C.C. Esau, J. Burchard, and P.S. Linsley MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators Mol Cell Biol 28 2008 5369 5380